Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
AGN Allergan plc daily Stock Chart
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-8.67 Insider Own0.20% Shs Outstand394.12M Perf Week4.75%
Market Cap122.74B Forward P/E19.23 EPS next Y16.19 Insider Trans- Shs Float393.20M Perf Month14.68%
Income-2997.10M PEG- EPS next Q3.36 Inst Own91.00% Short Float1.57% Perf Quarter1.78%
Sales14.93B P/S8.22 EPS this Y-40.80% Inst Trans3.06% Short Ratio1.31 Perf Half Y-0.53%
Book/sh184.31 P/B1.69 EPS next Y5.00% ROA2.60% Target Price363.93 Perf Year16.69%
Cash/sh5.25 P/C59.27 EPS next 5Y9.00% ROE5.30% 52W Range237.50 - 340.34 Perf YTD20.99%
Dividend0.20 P/FCF39.52 EPS past 5Y-42.20% ROI-2.70% 52W High-8.49% Beta0.68
Dividend %0.06% Quick Ratio1.90 Sales past 5Y36.10% Gross Margin63.00% 52W Low31.13% ATR12.26
Employees21600 Current Ratio2.00 Sales Q/Q90.10% Oper. Margin-22.90% RSI (14)58.92 Volatility3.33% 3.66%
OptionableYes Debt/Eq0.59 EPS Q/Q46.60% Profit Margin20.90% Rel Volume2.23 Prev Close311.43
ShortableYes LT Debt/Eq0.56 EarningsNov 04 BMO Payout0.00% Avg Volume4.74M Price311.43
Recom1.60 SMA202.27% SMA508.34% SMA2004.15% Volume0 Change0.00%
Nov-24-15Reiterated Mizuho Buy $340 → $354
Nov-13-15Reiterated Mizuho Buy $337 → $340
Oct-28-15Reiterated Leerink Partners Outperform $311 → $342
Oct-09-15Initiated Mizuho Buy
Sep-29-15Initiated Nomura Buy
Aug-07-15Reiterated RBC Capital Mkts Outperform $361 → $375
Aug-07-15Reiterated Deutsche Bank Buy $346 → $350
Aug-03-15Resumed JP Morgan Overweight $375 → $400
Jul-28-15Reiterated Leerink Partners Outperform $354 → $388
Jul-28-15Reiterated Canaccord Genuity Buy $352 → $396
Jul-17-15Downgrade RBC Capital Mkts Top Pick → Outperform $361
Nov-25-15 08:00AM  Allergan and Rugen Therapeutics Announce Collaboration to Discover and Develop Ground-Breaking Medicines to Treat Autism Spectrum Disorders and Obsessive-Compulsive Disorders PR Newswire
07:25AM  In the aftermath of Pfizergan comes renewed interest in Shaxalta at
07:15AM  Putins Rage and DraftKings/FanDuel in Court5 Things to Know Today at Fortune
06:47AM  Bring on your bearish headlines this bull market doesnt care at MarketWatch
12:00AM  Mylan, Bruised by Failed Perrigo Bid, Set for Face-Off on Assets at Bloomberg
Nov-24-15 11:47PM  [$$] At Skadden, Tax Law Isnt So Boring as Inversions Raise the Stakes at The Wall Street Journal
11:47PM  Pfizers Allergan Deal Offers Ireland Few New Benefits at The Wall Street Journal
07:16PM  Pfizer's Allergan Deal Offers Ireland Few New Benefits at The Wall Street Journal
06:48PM  Big Fees for Pfizer-Allergan Deal at The Wall Street Journal
05:43PM  Ireland's Market Outpaces Europe As Economy Recovers at Investor's Business Daily
05:17PM  Baxalta joins biotech M&A talk
04:49PM  Senate Panel to Take On Inversions in Review of Global Taxation at Bloomberg
04:19PM  Pfizers Allergan Deal is an Even Bigger Tax Dodge Than Its Claiming at Fortune
04:09PM  The reason Pfizer doesn't have to care what politicians say about its $160 billion merger
04:08PM  Billionaire James Dinan Loaded Up On These Stocks For Q4 at Insider Monkey
04:01PM  Healthcare Sector Rebounded, Intuit Led Tech Sector to 0.73% Gain
03:58PM  Are Markets Ready for a December Rate Hike?
03:16PM  Will Zoetis Derail the Allergan-Pfizer Merger? at
03:00PM  Political risk clouds Pfizer-Allergan deal at Financial Times
02:22PM  Street Talk: AGN, LOW & more
02:19PM  [$$] Pfizer's Next Step: Break Up at The Wall Street Journal
02:18PM  Pfizer's Tax Inversion Isn't A Miracle Drug: Just Ask Monsanto And Towers Watson at Forbes
02:18PM  Pfizer's Tax Inversion Isn't A Miracle Drug: Just As Monsanto And Towers Watson at Forbes
02:14PM  Corporate tax: The $240bn black hole at Financial Times
02:04PM  Nobody really cares if Pfizer stiffs Uncle Sam
01:49PM  Obama should close Pfizer's tax loophole at Financial Times
01:45PM  Inversions divert tax dollars and undermine the USA's reputation at USA TODAY
01:10PM  TIMELINE-Saunders gets key job as Pfizer, Allergan combine (Nov. 23)
12:56PM  Allergan represents growth, not just tax benefit
12:53PM  Tuesday links: good storytellers
12:09PM  Forget Allergan & Pfizer, Buy These Drug Stocks Instead
11:59AM  Valeant Pharmaceuticals: Ackman Ups Stake, While ValueAct Digs In
11:56AM  What You Need To Know About Pfizer's Tax-Driven Merger at Forbes
11:48AM  3 Stocks in the S&P 500 with a 100% Buy Rating: Should You Bite? at TheStreet
11:30AM  The runaway inversion craze, in three charts at CNBC
11:24AM  Jim Cramer Says Skyworks, Apple and Costco Are All Going Higher at TheStreet
11:10AM  Pfizer, Allergan deal comes under harsh criticism (Video) at
11:01AM  Pfizer-Allergan: Why Growth At Any Price Is A Dangerous Game at Forbes
10:53AM  Allergan Deal Boosts Pfizer's Long-Term Outlook: Credit Suisse at
10:46AM  Markets gap down on global tensions; Pfizer controversy deepens; and Black Friday retailer tricks
09:52AM  Basics of the Allergan-Pfizer Merger
09:50AM  The Allergan-Pfizer Merger: Another Big Inversion Transaction
09:44AM  Faber Report: Pfizer, Allergan follow up
09:37AM  Clinton, Trump tax comments 'a little rich': CEO at CNBC
09:30AM  Zacks Industry Outlook Highlights: Valeant, Pfizer, Allergan, AbbVie and Gilead
09:15AM  Deals of the Day: Pfizer's Future, Petco's Buyers, Activists in the News at The Wall Street Journal
08:54AM  Here's What Pfizer Is Really Buying With Its Purchase of Allergan at Motley Fool
08:42AM  Its time to lighten the load on these 10 stocks at MarketWatch
08:30AM  Major Indexes Finish Mixed On Light Stock Volume at Investor's Business Daily
08:24AM  Pfizer Finally Gets What it Wants: Lower Taxes -- Podcast at The Wall Street Journal
08:23AM  Pfizer-Allergan Deal Is About Tax Inversion, Financial Engineering at TheStreet
07:36AM  Russians Violate Turkish Airspace - Seconds Later - BOOM! Try the Potato/Escarole Soup
07:04AM  How to stop Pfizers faux-Irish tax ripoff at MarketWatch
07:04AM  How to stop Pfizers faux-Irish tax ripoff
06:32AM  Ask Matt: Is Pfizer a better investment now? at USA TODAY
06:04AM  ALLERGAN PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officer
05:16AM  Germany's Schaeuble says need to ensure tax base doesn't erode Reuters
12:33AM  [$$] Pfizer and Allergan: How the Deal Adds Up at The Wall Street Journal
12:30AM  [$$] Pfizer and Allergan to Merge in $155 Billion Inversion Deal at The Wall Street Journal
12:28AM  [$$] Pfizer Inversion Puts Pressure on U.S. Lawmakers to Revamp Tax Rules at The Wall Street Journal
Nov-23-15 10:42PM  Most Asian stock markets lower as commodity slump weighs
08:45PM  U.S. politicians slam tax-avoiding Pfizer-Allergan deal Reuters
08:38PM  What the Merger of Pfizer and Allergan Means for R&
08:26PM  [$$] Pfizer Weighs Splitting Up New Drug Behemoth at The Wall Street Journal
08:24PM  Pharma ETFs Pop Amid Pfizer-Allergan $160 Bil Deal at Investor's Business Daily
08:17PM  Experts: U.S. unlikely to block Pfizer-Allergan deal at USA TODAY
07:08PM  Cramer Remix: The newest king of the food aisle at CNBC
06:52PM  Pfizer seeks Washington support for $160bn Allergan deal at Financial Times
06:49PM  Pfizer to buy Allergan in $160 billion deal Reuters
06:22PM  Cramer: Can Pfizer reinvent itself with Allergan? at CNBC
06:22PM  Why Pfizer's talking about breaking up on the same day it announced a $160 billion merger
06:02PM  U.S. Republican Trump calls Pfizer deal to move tax base overseas 'disgusting' Reuters
06:00PM  Market dislikes Allergan-Pfizer deal: Cramer
05:42PM  Stocks give up an early gain and end lower; GameStop sinks at Los Angeles Times
05:31PM  Politicians slam tax-avoiding Pfizer-Allergan mega-deal Reuters
05:29PM  Like Drug Companies, Big Chipmakers Are Planning To Spend On M&A Instead of R&D at Forbes
05:23PM  Pfizer, Allergan Seal $160 Billion Tax-Inversion Deal at Investor's Business Daily
05:19PM  Digital downloads weigh on GameStop at Financial Times
05:17PM  Business Highlights
05:03PM  Train Reading: It's All in Your Mind at The Wall Street Journal
05:00PM  Stocks End Modestly Lower; Pfizer Deal Eyed
04:53PM  [$$] Pfizer Inversion Pressures Tax-Rule Revamp at The Wall Street Journal
04:45PM  Stocks end slightly lower; consolidate previous weeks big gains at MarketWatch
04:42PM  US STOCKS-Wall St falls after strong week; Pfizer and Allergan drag
04:35PM  [$$] Pfizer and Allergan: How the Deal Adds Up at The Wall Street Journal
04:27PM  Stocks slip after year's biggest week of gains at USA TODAY
04:24PM  Merger With Pfizer Could Boost Allergan's Credit Rating at
04:20PM  Pfizer and Allergan merge in $160B tax inversion deal at USA TODAY
04:20PM  Investors Arent Convinced the Pfizer-Allergan Deal is a Go at Fortune
04:20PM  What you need to know about the merger of Pfizer and Allergan at Los Angeles Times
04:11PM  Mega pharma deal boosts biotech shares, but pharma shares trade mixed at USA TODAY
04:08PM  IBD Stocks On The Move: New Highs & Lows, Rebounds at Investor's Business Daily
04:00PM  STOCKS GO NOWHERE: Here's what you need to know
03:41PM  US STOCKS-Wall Street falls after strong week, Pfizer and Allergan drag
03:31PM  Billionaire Daniel S. Ochs Biggest Bets For Q4 at Insider Monkey
03:30PM  Pfizer-Allergan Deal Puts Focus on Inversions
03:30PM  Fitbit, Chipotle Lead 5 Stocks With Big-Volume Action
03:28PM  Donald Trump slams Pfizer's 'disgusting' mega-merger
03:20PM  Pfizer to buy Allergan for $160 billion at
03:18PM  World's drug market shaken up by this man at USA TODAY
Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. The North American Brands segment provides patented and off-patent trademarked pharmaceutical products primarily under the Dalvance, Bystolic, Canasa, Carafate, Daliresp, Fetzima, Linzess, Namenda, Namenda XR, Saphris, Teflaro, Viibryd, Actonel, Asacol HD, Atelvia, Delzicol, Doryx, Estrace Cream, Enablex, Lo Loestrin Fe, and Minastrin 24 Fe brands. The North American Generics and International segment develops, manufactures, and sells generic, branded generic, and OTC pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products primarily to independent pharmacies, pharmacy chains and buying groups, and physician's offices. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, gastroenterology, urology, and dermatology areas. The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order retailers, government agencies, and managed healthcare providers. It has collaboration agreements with Amgen, Inc.; Ironwood Pharmaceuticals; Sanofi-Aventis U.S. LLC; and Trevena, as well as a research collaboration with Humana Inc. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Parsippany, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PYOTT DAVID E IChairman of the Board and CEOFeb 20Option Exercise0.001,3790166,379Feb 24 09:52 PM
Gangolli Julian SCVP & Pres, North AmericaFeb 20Option Exercise0.0051402,418Feb 24 09:44 PM